CURRICULUM VITAE

**Juan Pablo Arnoletti, M.D.**

**March 2023**

**E-mail** juanpablo.arnoletti@orlandohealth.com

**Position** Chair of Surgical Oncology

 Orlando Health Cancer Institute

 Professor of Surgery

 University of Central Florida College of Medicine

 1400 S Orange Ave, MP 700

 Orlando, FL 32806

 Tel: (321) 841-7229

**EDUCATION**

3/84 – 6/92 University of the Republic Medical School

#  Montevideo, Uruguay

 M.D.

 3/81-12/83 Crandon Institute

 Montevideo, Uruguay

 Bachelor in Biological Sciences

 12/81 University of Cambridge, London

 Certificate of Proficiency in English

**POSTGRADUATE TRAINING**

7/93-6/94Research Fellow, Department of Surgery

 Medical College of Pennsylvania

 Philadelphia, Pennsylvania

7/97-6/98 Research Fellow, Department of Surgery

 MCP-Hahnemann University

 Philadelphia, Pennsylvania

7/94-6/00 Resident, General Surgery

 MCP-Hahnemann University

 Philadelphia, Pennsylvania

 7/00-6/02 Fellow, Surgical Oncology

 Fox Chase Cancer Center

 Philadelphia, Pennsylvania

**ACADEMIC AND EMPLOYMENT POSITIONS**

### 3/87-5/93 Instructor of Anatomy

 University of the Republic Medical School, Montevideo, Uruguay

7/99-6/00 Member Graduate Medical Education Committee

 MCP- Hahnemann School of Medicine, Philadelphia, PA

7/00-6/02 Clinical Instructor – Department of Surgery

 Temple University Medical School, Philadelphia, PA

10/02- 6/08 Assistant Professor, Department of Surgery - University of Alabama at Birmingham

6/08-7/12 Associate Professor, Department of Surgery – University of Alabama at Birmingham (tenured)

12/02-7/12 Co-Chair Sarcoma Working Group-University of Alabama at Birmingham

Comprehensive Cancer Center

7/03-7/12 Director, Surgical Oncology Laboratory, University of Alabama at Birmingham

7/04-7/12 Member Gastrointestinal Malignancy Working Group, University of Alabama at

 Birmingham Comprehensive Cancer Center

3/06-7/12 Associate Director; Co-Principal Investigator University of Alabama at Birmingham T32 Surgical Oncology Training Grant

2010-2012 Co-Director Clinical Core UAB Pancreatic Cancer NCI-SPORE

2004-2012 National Comprehensive Cancer Network – Member Pancreatic Cancer and Colorectal Cancer Panels

2012-2021 Chief of Surgical Oncology, Advent Health Cancer Institute, Orlando, FL

2012-present Professor of Surgery, University of Central Florida College of Medicine

2012-2021 Chairman Gastrointestinal Cancer Leadership Committee, Advent Health Cancer Institute

2013-present Professor of Surgery, Florida State University

2017-2021 Chair Comprehensive Cancer Center, Advent Health Cancer Institute,

 Orlando, FL

2017-2021 Cancer Liaison Physician, Advent Health Cancer Institute, Commission on Cancer, American College of Surgeons

2021-2022 Director of GI Oncology, Orlando Health Cancer Institute, Orlando, FL

2022-present Chair of Surgical Oncology, Orlando Health Cancer Institute, Orlando, FL

**CERTIFICATION**

1993 USMLE 1; USMLE 2

 Educational Commission for Foreign Medical Graduates,

 Certificate # 0-494-250-4; issued 8/26/93

1994 USMLE 3

 Advanced Trauma Life Support (re-certified 1998)

 Advanced Cardiac Life Support (re-certified 2000)

 2001 American Board of Surgery – Re-certified 2011

**LICENSURE**

1997 Pennsylvania: MD-061685-L

2002 Alabama: 24732

2012 Florida: ME 113251, active

**MEMBERSHIP IN PROFESSIONAL SOCIETIES**

American College of Surgeons, Fellow, 2005

Society of Surgical Oncology, 2001 – Member Fellowship and Research Grant Committee

Society for Surgery of the Alimentary Tract, 2002

American Society of Clinical Oncology, 2001

Association for Academic Surgery, 2002

American Association for Cancer Research, 2004

Americas Hepato-Pancreato-Biliary Association, 2008

Society of University Surgeons, 2010

**AWARDS**

1994AmericanAssociationfor Cancer Research, Upjohn Company Travel Award

2001 Berlex Oncology Foundation Award, Genetics in Oncology

2002 Philadelphia Academy of Surgery, Resident’s Competition Award

2004 John W. Kirklin Research and Education Fellowship Award

2005 James Ewing Oncology Fellowship Award for Basic Research – Society of Surgical

Oncology

2006 to 2012 Birmingham Magazine Best Doctors in America

2012 to 2022 Orlando Magazine Best Doctors in America

2014-2015 Attending of the Year – Florida Hospital General Surgery Residency Program

2015-2016 Attending of the Year – Florida Hospital General Surgery Residency Program

**Mentee Awards:**

2006 Best Paper Award and Harvey Baker Travel Award, Society of Surgical Oncology 60th

Annual Meeting, Washington, DC, 2007 March. (Ching-Wei Tzeng, MD, Mentee

Recipient)

2011 William A. Maddox Best Oncology Abstract Award – American College of Surgeons

Alabama Chapter Meeting, Destin, FL, 2011 June. (Lilian Azih, MD, Mentee recipient)

2012 Best Presentation – Resident Research Day – Department of Surgery – University of Alabama at Birmingham, 2012, May (Lilian Azih, MD, Mentee recipient)

2020 Edward Copeland Best Basic Science Abstract, Florida Chapter, American College of Surgeons, Orlando, FL, 2020 March. (Joseph Reza, MD, Mentee recipient)

###### GRANTS

1997-1998 House Staff Research Program Grant, MCP-Hahnemann School of Medicine

1/06-6/08 P20 CA10195-01 (Buchsbaum, PI) NIH/NCI $35,000

Analysis of aberrant EGFR signaling in locally advanced pancreatic adenocarcinoma as a prognostic factor of response to cetuximab-based multimodality therapy. Role: Co-Investigator

1/06-6/08 P20 CA101955 (Arnoletti, PI) NIH – Bristol-Myers Squibb $120,000 Phase I clinical study evaluating the role of an ant-epidermal growth factor receptor antibody, C225, as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Role: Principal Investigator

7/07 - 7/12 T32 CA91078 (Bland, PI; Arnoletti, Co-PI) NIH $314,902

University of Alabama at Birmingham Research Training Program in Surgical Oncology. Role: Co-Principal Investigator; Co-Director.

2009 UAB 0808 (Arnoletti, PI) OSI Pharmaceuticals, Inc $310,000

A phase II study of short-course preoperative erlotinib followed by post-operative erlotinib-gemcitabine in patients with resectable pancreatic adenocarcinoma

Role: Principal Investigator

2010 UAB 0855 (Posey, PI) Pfizer $ 31,128

Pilot trial of neoadjuvant sunitinib in patients with bulky GIST

Role: Co-Investigator

2011 UAB 1055 BAY 73-4506/14874 (Arnoletti, Institutional PI) Bayer $39,101

A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sutinib

2011 Pre-clinical studies of anti-ErbB3 antibody (MM-121) in pancreatic ductal

adenocarcinoma. (Frolov PI; Arnoletti Co-PI)

Merrimack Pharmaceuticals $140,000

2015-16 Phi Beta Psi PI: Litherland

Myeloid derived immunosuppressor cell (MDSC) characterization in pancreatic ductal adenocarcinoma (PDAC)

Role: Co-Investigator $27,000

2016 Florida Hospital Foundation PI: Arnoletti, Literland

*Correlating tumor cell and tumor immune responses in pancreatic cancer*

Role: Co-Principal Investigator $30,000

2016–18  Florida Hospital Foundation PI: Litherland/Arnoletti

*Identification of altered lipids for early diagnosis of pancreatic cancer*.

Role: Co-Principal Investigator  $100,000

2016–17   Phi Beta Psi  PI: Litherland

*Novel Actin Polymerization Inhibitor Test in Pancreatic Cancer Mixed Cell Reaction Culture System.*

Role: Co-Investigator $20,000

 2017-18  Fraternal Order of Eagles PI: Arnoletti/Litherland

*Treatment of Pancreatic Cancer to Prevent Recurrence and Metastasis*.

Role: Co-Principal Investigator  $56,000

2018-21 Florida Department of Health-Bankhead-Coley Discovery Research 8BC05

PI: Phanstiel, O (UCF)

Developing polyamine transport inhibitors for the treatment of human cancers.

Role: Co-Investigator $131,000

2020-2021 Bristol Myers Squibb BMS CA025-016 PI: Litherland

Disrupting portal blood pancreatic cancer circulating tumor cell cluster formation and survival with myeloid cell directed immunotherapy

Role: Co-Investigator $100,000

|  |  |  |
| --- | --- | --- |
|  |   |   |
|  |
|  |   |
|  |

**COURSES**

2001 Society of Surgical Oncology / United States Surgical Endosurgery Course, Norwalk, Connecticut

2001 American College of Surgeons: Ultrasound for Surgeons, Lake Geneva, Wisconsin

2004 Ethicon Endo-Surgery Hand Assisted Laparoscopic Colon Surgery, Cincinnati, Ohio

2004 American College of Surgeons, Young Surgical Investigators Conference, Leesburg, Virginia

2004 American College of Surgeons: Abdominal Ultrasound: Transabdominal/Intraoperative/Laparoscopic, New Orleans, Louisiana

2009 Console Surgeon da Vinci Surgical System, Tampa, Florida

2013-5 Advances in minimal access approaches in the management of hepato-pancreato-biliary and gastrointestinal diseases. Course Co-Chair. Florida Hospital, Orlando, Florida.

2015 Physician Leader Development Course, Florida Hospital, Gen. Mark Hertling, Course Director

2017 1st Annual Hepatobiliary Course: Medical and Surgical Updates. Moderator. Florida Hospital, Orlando, Florida.

**LEADERSHIP**

2012-2021 Advent Health Gastrointestinal Cancer Leadership Committee – Chairman

 2012-2021 Advent Health Cancer Institute Governance Council – Member

 2013-2021 Advent Health Blood Transfusion Committee – Member

 2013-2021 Advent Health Orlando Physician Advisory Council – Member

 2015-2021 Advent Health Research Leaders Advisory Council – Member

 2015-2021 Advent Health Global Health Forum – Member

 2015-2017 North Orlando Rowing Club – Board Member

 2017-2021 Advent Health Cancer Institute Protocol Review Committee – Member

2017-2021 Comprehensive Cancer Center Chair, Cancer Liaison Physician, Commission on Cancer, American College of Surgeons

 2018-2020 Annunciation Catholic School – Board Member

 2019-2021 Advent Health Cancer Institute Foundation – Member

 2021-present Physician Leadership Group – Orlando Health Cancer Center

**SELECTED INVITED LECTURES**

 - Surgical treatment of metastatic colorectal cancer. 1st International Congress. Hospital General de Mexico, Leon, Mexico, 2005 February.

- Biology and treatment of pancreatic cancer. 58th Uruguayan Surgery Meeting. Montevideo, Uruguay, 2007 November.

- Multi-disciplinary treatment of soft tissue sarcomas. 58th Uruguayan Surgery Meeting. Montevideo, Uruguay, 2007 November.

- Multimodality treatment of esophageal cancer. 1st International Surgery Week. Instituto Nacional de la Nutricion Salvador Zubiran. Mexico City, Mexico, 2008 February.

- Gastrointestinal sarcomas. 1st International Surgery Week. Instituto Nacional de la Nutricion Salvador Zubiran. Mexico City, Mexico, 2008 February.

- Treatment of gastrointestinal stromal tumors and visceral sarcomas. XXXI International Surgery Course. Hospital 12 de Octubre, Madrid, Spain, 2008 May.

- Surgical treatment of colorectal cancer liver metastasis. XXXI International Surgery Course. Hospital 12 de Octubre, Madrid, Spain, 2008 May.

- Pancreatic Cystic Neoplasms. XXXII International Surgery Course. Hospital 12 de Octubre, Madrid, Spain, 2009 May.

- Multi-disciplinary treatment of retroperitoneal sarcomas. XXXII International Surgery Course. Hospital 12 de Octubre, Madrid, Spain, 2009 May.

- Pancreas Cancer 2009 is anything changing: New paradigms in pre and postoperative therapy. American College of Surgeons 95th Annual Clinical Congress, Chicago, Illinois, 2009 October.

- Advanced Laparoscopy Course: Left upper-quadrant organs and Laparoscopic pancreatic surgery. Latin American Surgical Federation. 60th Uruguayan Surgery Meeting, Punta del Este, Uruguay, 2009 November

- Molecular Biology of Pancreatic Cancer; Cystic Pancreatic Neoplasms; Anastomotic Techniques after pancreatico-duodenectomy. 27th International Meeting Cirugia de Cordoba del Bicentenario, Cordoba, Argentina, 2010 July.

- Emergencies in Oncologic Colorectal Surgery: Perforation and Bleeding. XIX Latin American Meeting of Surgery (FELAC) and XXXV International Surgical Congress Mexican Society of General Surgery, Veracruz, Mexico, 2011 November.

- Current Management of Soft Tissue Sarcomas. Principles of Surgical Oncology Postgraduate Course. XIX Latin American Meeting of Surgery (FELAC) and XXXV International Surgical Congress Mexican Society of General Surgery, Veracruz, Mexico, 2011 November.

- Current Management of Gastrointestinal Stromal Tumors. Principles of Surgical Oncology Postgraduate Course. XIX Latin American Meeting of Surgery (FELAC) and XXXV International Surgical Congress Mexican Society of General Surgery, Veracruz, Mexico, 2011 November.

- Master Lecture: Obstructive Jaundice. XIX Latin American Meeting of Surgery (FELAC) and XXXV International Surgical Congress Mexican Society of General Surgery, Veracruz, Mexico, 2011 November.

- Master Lecture: Education and Training of the Young Surgeon as a Lifestyle. XIX Latin American Meeting of Surgery (FELAC) and XXXV International Surgical Congress Mexican Society of General Surgery, Veracruz, Mexico, 2011 November.

- Progress and Promise in Pancreatic Cancer Treatment – UAB Comprehensive Cancer Center Annual Report and Celebration, Birmingham, Alabama, 2011 December.

- Professionalism in Surgery – 63rd Uruguayan Surgery Meeting, Montevideo, Uruguay, 2012 November

- Update in Pancreatic Cancer Treatment – Best of ASCO 2013, Orlando, Florida, 2013 June

-Innovations in Colorectal Surgery - Which first: colon, liver or synchronous resection for metastatic colorectal cancer, Orlando, Florida, 2013 October

- Update in Pancreatic Cancer Treatment – Best of ASCO 2014, Orlando, Florida, 2014 June

- Digestive Surgery Course: Pancreatic surgery, open, robotic or laparoscopic? National Gastroenterology Week, Mexican Society of Gastroenterology, Cancun, Mexico, 2014 November

- Minimally invasive management of pancreatic diseases. National Gastroenterology Week, Mexican Society of Gastroenterology, Cancun, Mexico, 2014 November

- Latin America HPB Course Instituto Nacional de la Nutricion: Live case demonstration and lecture: Distal Pancreatectomy. Surgical management of infected pancreatic necrosis, Mexico City, Mexico, 2015 May

- Surgical treatment of duodenal polyps. North meets South Gastrointestinal Medical and Surgical Symposium, Florida Hospital, Orlando, Florida, February 2016

- Multidisciplinary treatment of soft tissue sarcomas. Florida Hospital Cancer Institute Grand Lecture Series. Orlando, Florida, March 2016

- Surgical treatment of pancreatic necrosis. East meets West Symposium, Florida Hospital, Orlando, Florida, October 2017

- Best of ASCO – Pancreatic Cancer, Florida Hospital, The Ritz-Carlton Hotel, Orlando, September 2018

-Current Treatment of Pancreatic Cancer. 73rd Uruguayan National Surgery Congress, December 2022.

-Minimally invasive management of walled-off pancreatic necrosis. 73rd Uruguayan National Surgery Congress, December 2022.

 **PUBLICATIONS**

Articles

1. Albo D, **Arnoletti JP**, Castiglioni A, Granick MS, Solomon MP, Rothman VL, Tuszynski GP. Thrombospondin (TSP) and transforming growth factor β-1 (TGF- β) promote human A549 lung carcinoma cell plasminogen activator inhibitor type-1 (Pal-1) production and stimulate tumor cell attachment *in vitro*. Biochem Biophys Res Comm203(2):857-865, 1994.

2. **Arnoletti JP**, Albo D, Jhala N, Granick MS, Solomon MP, Atkinson B, Rothman VL, Tuszynski GP. Computer-assisted image analysis of tumor sections for a new thrombospondin receptor. Am J of Surgery 168:433-436, 1994.

3. **Arnoletti JP**, Albo D, Granick MS, Solomon MP, Castiglioni A, Rothman VL, Tuszynski GP. Thrombospondin and transforming growth factor-β 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer 76(6):998-1005, 1995.

4. **Arnoletti JP** and Brodsky J. Reduction of transfusion requirements during major hepatic resection for metastatic disease. Surgery 125(2):166-171, 1999.

5. **Arnoletti JP**, Karam J, Brodsky J. Early postoperative complications of splenectomy for hematologic disease. Am J Clin Oncol 22: 114-118, 1999.

# 6. **Arnoletti JP** and Brodsky J. Surgical treatment of benign hepatic mass lesions. Am Surg 65:431-433, 1999.

1. **Arnoletti JP** and Whitman G. Heparin-induced thrombocytopenia in coronary bypass surgery. Ann Thoracic Surg 68:576-578, 1999.
2. **Arnoletti JP,** Hoffman JP, Ross, E, Kagan S, Meropol N, Freedman G, Eisenberg B. Preoperative chemoradiation in the management of adenocarcinoma of the body of the pancreas. Am Surg 68:330-336, 2002.
3. Frolov A, Chahwan S, Ochs M, **Arnoletti JP**, Pan ZZ, Favorova O, Fletcher J, von Mehren M, Eisenberg E, Godwin AK. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther 2:699-709, 2003.
4. **Arnoletti JP** and Jhala N. Retroperitoneal hemangiopericytoma. J Am Coll Surg 197:687-688, 2003.
5. **Arnoletti JP**, Buchsbaum DJ, Huang Z, Hawkins AE, Khazaeli MB, Kraus MH, Vickers SM. Mechanisms of resistance to Erbitux (Anti-EGFR) combination therapy in pancreatic adenocarcinoma cells. J Gastrointest Surg 8:960-970, 2004.
6. Ettinger DS, **Arnoletti** **JP**, Gockerman JP, Handorf C, Havlin KA, Jacobs CD, Javle M, Kvols L, Lenzi R, Rashid A, Rhoades CA, Ridge JA, Saltz L, Shulman LN, Sondak VK, Thompson JA, Twardowski P, Zhen W. Occult primary cancer clinical practice guidelines. J Natl Compr Canc Netw 3: 214-33, 2005.
7. Tarn C, Merkel E, Canutescu AA, Shen W, Skorobogatko Y, Heslin MJ, Eisenberg B, Birbe R, Patchefsky A, Dunbrack R, **Arnoletti JP**, von Mehren M, Godwin AK. Analysis of KIT mutations in sporadic and familial GIST: therapeutic implications using protein modeling. Clin Cancer Res 11:3668-77, 2005.
8. Heslin MJ, Hawkins A, Boedefeld W, **Arnoletti JP**, Frolov A, Soong R, Urist MM, Bland KI.Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. Ann Surg 241:941-947, 2005.
9. **Arnoletti JP**, Upson J, Babb JS, Bellacosa A, Watson JC. Differential stromal and epithelial localization of cyclooxygenase-2 (COX-2) during colorectal tumorigenesis. J Exp Clin Cancer Res 24:279-288, 2005.
10. **Arnoletti JP**, Bland KI. Neo-adjuvant and adjuvant therapy for rectal cancer. Surg Oncol Clin North Am 15:147-57, 2006.
11. Stewart AE, Heslin MJ, Arch J, Jhala N, Ragland B, Gomez F, Bland KI, Heslin MJ, **Arnoletti JP**. Cyclooxygenase-2 (COX-2) Expression and Clinical Outcome in Gastrointestinal Stromal Tumors (GIST). J Gastrointest Surg 10:315-19, 2006.
12. Meara R, Reddy V, **Arnoletti JP**, Jhala D, Varadarajulu S, Jhala N. Diagnosis of Hairy Cell Leukemia by Endoscopic Ultrasound Guided Fine Needle Aspiration: A case report and review of recent literature. Cytojournal 3:1-5, 2006.
13. Tzeng CD, Fiveash JB, Popple RA, **Arnoletti JP**, Russo SM, Urist MM, Bland KI, Heslin MJ. Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. Cancer 107:371-79, 2006.
14. Gomez-Rivera F, Stewart AE, **Arnoletti JP**, Vickers S, Bland, KI, Heslin MJ. Surgical treatment of pancreatic endocrine neoplasms. Am J Surg 193:460-65, 2007.
15. Tzeng CD, Frolov A, Frolova N, Jhala NC, Howard JH, Buchsbaum DJ, Vickers SM, Heslin MJ, **Arnoletti JP**. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 141:464-69, 2007.
16. Eloubeidi MA, Varadarajulu S, Desai S, Shirley R, Heslin MJ, Mehra M, **Arnoletti JP**, Eltoum I, Wilcox CM, Vickers SM. A prospective evaluation of an algorithm incorporating routine preoperative endoscopic ultrasound-guided fine needle aspiration in suspected pancreatic cancer. J Gastrointest Surg 11:813-19, 2007.
17. Tzeng CD, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ, **Arnoletti JP**. Pancreatic cancer epidermal growth factor receptor (*EGFR*) intron 1 polymorphism influences postoperative patient survival and *in vitro* erlotinib response. Ann Surg Oncol 14:2150-8, 2007.
18. Frolov A, Schuller K, Tzeng CD, Cannon EE, Ku BC, Howard JH, Vickers SM, Heslin MJ, Buchsbaum DJ, **Arnoletti JP**. ErbB3 expression and dimerization with EGFR determine pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther 6:548-54, 2007.
19. Tzeng CD, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ, **Arnoletti JP**. *EGFR* genomic gain and aberrant pathway signaling in pancreatic cancer patients. J Surg Res 143:20-6, 2007.
20. DeRosier LC, Vickers SM, Zinn KR, Huang Z, Wang W, Grizzle WE, Sellers J, Stockard CR, Zhou T, Oliver PG, **Arnoletti P**, LoBuglio AF, Buchsbaum DJ.TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol Cancer Ther 6:3198-207, 2007.
21. Engstrom PF, **Arnoletti** **JP**, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Fakih MG, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saltz L, Shibata D, Skibber JM, Venook AP. Colon cancer. J Natl Compr Canc Netw 5:884-925, 2007.
22. Engstrom PF, **Arnoletti** **JP**, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Fakih MG, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saltz L, Shibata D, Skibber JM, Venook AP Rectal cancer. J Natl Compr Canc Netw 5:940-81, 2007.
23. Tempero M, **Arnoletti** **JP**, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C.. Pancreatic adenocarcinoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 5:998-1033, 2007.
24. Howard JH, Gonzalez Q, **Arnoletti JP**, Russo S, Fiveash JB, Bland KI, Heslin MJ. Prognostic factors and preoperative radiation therapy associated with sphincter preservation in patients with resectable rectal cancer. Am J Surg 195: 239-243, 2008.
25. Meara RS, Jhala N,Eltoum I, **Arnoletti JP**, Jhala D. Fine needle aspiration of an axillary lymph node in a patient suspected of having metastatic cancer of unknown primary. Cytopathology 19: 192-196, 2008.
26. Varadarajulu S, **Arnoletti JP**. Laparoscopic assistance for endoscopic resection of early stage esophageal cancer (with video). Gastrointest Endosc 68: 181-183, 2008.
27. Howard JH, Tzeng CW, Smith JK, Eckhoff DE, Bynon JS, Wang T, **Arnoletti JP**, Heslin MJ. Radiofrequency ablation for unresectable tumors of the liver. Am Surg 74: 594-600, 2008.
28. Howard JH, Frolov A, Tzeng CW, Stewart A, Midzak, A, Majmundar A, Godwin AK, Heslin MJ, Bellacosa A, **Arnoletti JP**. Epigenetic downregulation of the DNA repair gene MED1/MBD4 in colorectal and ovarian cancer. Cancer Biol Ther 8: 94-100, 2009.
29. Pawar P, Ma L, Byon CH, Liu H, Ahn EY, Jhala N, **Arnoletti JP**, McDonald JM, Chen Y. Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin Cancer Res 15:1288-1296, 2009.
30. Finan KR, Cannon EE, Kim EJ, Wesley MM, **Arnoletti JP**, Heslin MJ, Christein JD. Laparoscopic and open distal pancreatectomy: a comparison of outcomes. Am Surg 75:671-679, 2009.
31. Engstrom PF, **Arnoletti** **JP**, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN clinical practice guidelines in oncology: rectal cancer. J Natl Compr Canc Netw 7: 838-81, 2009.
32. Engstrom PF, **Arnoletti** **JP**, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN clinical practice guidelines in oncology: colon cancer. J Natl Compr Canc Netw 7: 778-831, 2009
33. Engstrom PF, **Arnoletti** **JP**, Benson AB 3rd, Berlin JD, Berry JM, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, Fuchs C, Grem JL, Knol JA, Leong LA, Lin E, Mulcahy MF, Rohren E, Ryan DP, Saltz L, Shibata D, Skibber JM, Small W, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN clinical practice guidelines in oncology. Anal Carcinoma. J Natl Compr Canc Netw 8: 106-20, 2010.
34. Eloubeidi MA, Luz LP, Crowe DR, Snowden C, Morgan DE, **Arnoletti JP**. Bilateral adrenal gland enlargement secondary to histoplasmosis mimicking adrenal metastases: Diagnosis with EUS-guided FNA. Diagnostic Cytopathology 38:357-359, 2010.
35. Frolov A, Liles JS, Kossenkov AV, Tzeng CD, Jhala N, Varadarajulu S, Eloubeidi M, Heslin MJ, **Arnoletti JP**. Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma. Am J Surg 200:398-405, 2010.
36. Liles JS, **Arnoletti JP**, Tzeng CD, Howard JH, Kossenkov AV, Kulesza P, Heslin MJ, Frolov A. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer Biol Ther 10: 555-563, 2010.
37. Tempero MA, **Arnoletti JP**, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 8:972-1017, 2010.
38. Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, **Arnoletti JP**, Christein JD, Vickers SM, Langmead CJ, Landsittel DP, Whitcomb DC, Grizzle WE, Lokshin AE. Serum Biomarker Panels for the Detection of Pancreatic Cancer. Clin Cancer Res 17: 805-816, 2011.
39. **Arnoletti JP**, Frolov A, Eloubeidi M, Keene K, Posey J, Wood T, Greeno E, Jhala N, Varadarajulu S, Russo S, Christein J, Oster R, Buchsbaum DJ, Vickers SM. A Phase I study evaluating the role of the anti-Epidermal Growth Factor Receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemother Pharmacol 67: 891-897, 2011.
40. Jing G, Yuan K, Turk A, Jhala N, **Arnoletti J**, Zhang K, McDonald J, Chen Y. Tamoxifen enhances therapeutic effects of gemcitabine on cholangiocarcinoma tumorigenesis. Lab Invest 91: 896-904, 2011.
41. Bang JY, Varadarajulu S, **Arnoletti JP**. Mucinous cystic neoplasm of the pancreas. Clin Gastroenterol Hepatol 9:80-1, 2011.
42. Liles JS, **Arnoletti JP**, Kossenkov AV, Mikhaylina A, Frost AR, Kulesza P, Heslin MJ, Frolov A. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma. Br J Cancer 105:523-33, 2011.
43. Benson AB 3rd, **Arnoletti** **JP**, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fleshman JW Jr, Fuchs CS, Grem JL, Knol JA, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett C; National Comprehensive Cancer Network. Colon Cancer. J Natl Compr Canc Netw 9:1238-90, 2011.
44. Benson AB 3rd, **Arnoletti** **JP**, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fakih MG, Fleshman JW Jr, Fuchs CS, Grem JL, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett C, Freedman-Cass DA. Anal Carcinoma, Version 2.2012: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10: 449-54, 2012.
45. Tempero MA, **Arnoletti** **JP**, Behrman SW, Ben-Josef E, Benson AB 3rd, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. Pancreatic Adenocarcinoma, Version 2.2012: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10: 703-13, 2012.
46. Azih LC, Broussard BL, Phadnis MA, Heslin MJ, Eloubeidi MA, Varadarajulu S, **Arnoletti JP**. Endoscopic ultrasound evaluation in the surgical treatment of duodenal and peri-ampullary adenomas. World J Gastroenterol 19: 511-15, 2013.
47. Reilly C, Zenoni S, Hasan MK, Varadarajulu S, Tran TA, de la Fuente SG, **Arnoletti JP**. Primary pancreatic Ewing’s sarcoma with portal vein tumor thrombosis. J Gastrointest Surg 17: 1015-9, 2013.
48. Zenoni SA, **Arnoletti** **JP**, de la Fuente SG. Recent developments in surgery: minimally invasive approaches for patients requiring pancreaticoduodenectomy**.** JAMA Surg 148: 1154-7, 2013.
49. Garcia PL, Council LN, Christein JD, **Arnoletti JP**, Heslin MJ, Gamblin TL, Richardson JH, Bjornsti MA, Yoon KJ. Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma. PLoS One 8: e78183, 2013.
50. De la Fuente SG, **Arnoletti JP**. Beyond cytology: why and when the oncologist requires core tissue. Gastrointest Endos Clin N Am 24:9-17, 2014.
51. Kim H, **Arnoletti JP**, Christein J, Heslin MJ, Posey JA, **Pednekar A**, Beasley TM, Morgan DE. Pancreatic adenocarcinoma: a pilot study of quantitative perfusion and diffusion weighted breath-hold magnetic resonance imaging. Abdom Imaging, 39:74-752, 2014.
52. Bang JY, Holt BA, Hawes RH, Hasan MK, **Arnoletti JP**, Christein JD, Wilcox CM, Varadarajulu S. Outcomes after implementing a tailored endoscopic step-up approach to walled-off necrosis in acute pancreatitis. Br J Surg, 101:1729-38, 2014.
53. Smith JP, **Arnoletti JP**, Varadarajulu S, Morgan DE. Post-pancreatitis fat necrosis mimicking carcinomatosis. Radiol Case Rep 3: 192, 2015.
54. Garcia PL, Miller AL, Kreitzburg KM, Council LN, Gamblin TL, Christein JD, Heslin MJ, **Arnoletti** **JP**, Richardson JH, Chen D, Hanna CA, Cramer SL, Yang ES, Qi J, Bradner JE, Yoon KJ. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene 35: 833-45, 2016.
55. **Arnoletti JP**, Zhu X, Almodovar AJ, Veldhuis P, Sause R, Corpus G, Chang JC, Fanaian N, Litherland SA. Portal Venous Blood Circulation Supports Immunosuppressive Environment and Pancreatic Cancer Circulating Tumor Cell Activation. Pancreas 46: 116-123, 2017.
56. Garcia PL, Miller AL, Gamblin TL, Council LN, Christein JD, **Arnoletti JP**, Heslin MJ, Reddy S, Richardson JH, Cui X, Waardenburg RC, Bradner JE, Yang ES. JQ1 induces DNA damage and apoptosis, and inhibits tumor growth in a patient-derived xenograft model of cholangiocarcinoma. Mol Cancer Ther 17: 107-118, 2018.
57. Reza JA, Fruchter S, Varadarajulu S, **Arnoletti JP**. A large intussuscepting gastric lipoma. J Gastrointest Surg 22: 1299-1300, 2018.
58. **Arnoletti** **JP**, Fanaian N, Reza J, Sause R, Almodovar AJ, Srivastava M, Patel S, Veldhuis PP, Griffith E, Shao YP, Zhu X, Litherland SA. Pancreatic and bile duct cancer circulating tumor cells (CTC) form immune-resistant multi-cell type clusters in the portal venous circulation. Cancer Biol Ther 19:887-97, 2018.
59. Smith K, Karimian-Azari E, LaMoia TE, Hussain T, Vargova V, Karolyi K, Veldhuis PP, **Arnoletti** **JP**, de la Fuente SG, Pratley RE, Osborne TF, Kyriazis GA. T1R2 receptor-mediated glucose sensing in the upper intestine potentiates glucose absorption through activation of local regulatory pathways. Mol Metabol 17:98-111, 2018.
60. Bang JY, **Arnoletti** **JP**, Holt BA, Sutton B, Hasan MK, Navaneethan U, Feranec N, Wilcox CM, Tharian B, Hawes RH, Varadarajulu S. An endoscopic approach compared to minimally invasive surgery reduces complications and costs for patients with necrotizing pancreatitis. Gastroenterology 156: 1027-1040, 2019.
61. Reza J, Almodovar A, Srivastava M, Veldhuis P, Patel S, Fanaian N, Zhu X, Litherland S, **Arnoletti JP**. K-RAS mutant gene found in pancreatic juice activated chromatin from peri-ampullary carcinomas. Epigenet Insights 12:2516865719828348, 2019.
62. Bang JY, Wilcox CM, **Arnoletti JP**, Varadarajulu S. Superiority of endoscopic interventions over minimally invasive surgery for infected necrotizing pancreatitis: a meta-analysis of randomized trials. Dig Endosc 32:298-308, 2020.
63. Gitto SB, Beardsley JM, Nakkina SP, Oyer JL, Cline KA, Litherland SA, Copik AJ, Khaled AS, Fanaian N, **Arnoletti JP**, Altomare DA. Identification of a novel IL-5 signaling pathway in chronic pancreatitis and crosstalk with pancreatic tumor cells. Cell Commun Signal 18:95, 2020.
64. Tran T, Rosales A, **Arnoletti JP**, Ouyang J, Hasan M. Concomitant neuroendocrine tumor and gastrointestinal stromal tumor in a duodenal fine needle aspiration: a cytologic clue for neurofibromatosis type 1. Diagn Cytopathology 49:E45-E48, 2021.
65. Bang JY, Krall K, Jhala N, Singh C, Tejani M, **Arnoletti JP**, Navaneethan U, Hawes R, Varadarajulu S. Comparing Needles and Methods of Endoscopic Ultrasound-Guided Fine-Needle Biopsy to Optimize Specimen Quality and Diagnostic Accuracy for Patients With Pancreatic Masses in a Randomized Trial. Clin Gastroenterol Hepatol 19:825-835, 2021.
66. Bang JY, Mel Wilcox C, **Arnoletti JP**, Varadarajulu S. Importance of disconnected pancreatic duct syndrome in recurrence of pancreatic fluid collections initially drained using lumen-apposing metal stents. Clin Gastroenterol Hepatol 19:1275-1281, 2021.
67. Permuth JB, Dezsi KB, Vyas S, Ali KN, Basinski TL, Utuama OA, Denbo JW, Klapman J, Dam A, Carballido E, Kim DW, Pimiento JM, Powers BD, Otto AK, Choi JW, Chen DT, Teer JK, Beato F, Ward A, Cortizas EM, Whisner SY, Williams IE, Riner AN, Tardif K, Velanovich V, Karachristos A, Douglas WG, Legaspi A, Allan BJ, Meredith K, Molina-Vega MA, Bao P, St Julien J, Huguet KL, Green L, Odedina FT, Kumar NB, Simmons VN, George TJ, Vadaparampil ST, Hodul PJ, **Arnoletti JP**, Awad ZT, Bose D, Jiang K, Centeno BA, Gwede CK, Malafa M, Judge SM, Judge AR, Jeong D, Bloomston M, Merchant NB, Fleming JB, Trevino JG, On Behalf Of The Florida Pancreas Collaborative. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer. Cancers (Basel) 13:809, 2021.
68. Bang JY, Wilcox CM, **Arnoletti JP**, Peter S, Christein J, Navaneethan U, Hawes R, Varadarajulu S. Validation of the Orlando Protocol for endoscopic management of pancreatic fluid collections in the era of lumen-apposing metal stents. Dig Endosc 34:612-21, 2022.
69. **Arnoletti JP**, Reza J, Rosales A, Monreal A, Fanaian N, Whisner S, Srivastava M, Rivera-Otero J,Yu G, Phanstiel O, Altomare DA, Tran Q, Litherland SA. Pancreatic ductal adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation. PLoS One 17(3):e0265725, 2022.
70. Dobrovolskaite A, Moots H, Tantak MP, Shah K, Thomas J, Dinara S, Massaro C, Hershberger PM, Maloney PR, Peddibhotla S, Sugarman E, Litherland S, **Arnoletti JP**, Jha RK, Levens D, Phanstiel O 4th. Discovery of anthranilic acid derivatives as difluoromethylornithine adjunct agents that inhibit far upstream element binding protein 1 (FUBP1) function. J Med Chem 24: 15391-415, 2022.

**Book Chapters**

**Arnoletti JP** and Goldberg M. Superior vena cava syndrome. Yang S and Cameron D [eds]: Current Therapy in Thoracic and Cardiovascular Surgery. Philadelphia, Mosby, 2004.

**Arnoletti JP** and Aiko S. Esophageal, gastric and pancreatic cancer. Rolandelli, Bankhead, Boullata, Compher (eds.): Clinical Nutrition: Enteral and Tube Feeding, 4th ed., Philadelphia, Elsevier, 2004.

Vickers SM, **Arnoletti JP**, Andersen DK, Brunicardi FC. Pancreas Anatomy and Physiology. Mulholland et al. Surgery: Scientific Principles and Practice, 4th ed., Philadelphia, Lippincot Williams & Wilkins, 2005.

**Selected Abstracts**

1. Innervation of the greater curvature of the stomach: The right gastro-epiploic pedicle. Asociacion Rioplatense de Anatomia - 34th Annual Meeting - Cordoba, Argentina, 1992 October.

1. Modulation of the expression of tumor-associated proteases in breast cancer: A role for thrombospondin and TGF-β. Society of University Surgeons - 36th Annual Residents’ Conference - Jackson, Mississippi, 1994 February.
2. Enhanced bone regeneration by derivatized dextran (CMDBS) is mediated by thrombospondin. Robert H. Ivy Society of Plastic Surgeons - 40th Annual Meeting Philadelphia, Pennsylvania, 1994 March.
3. Thrombospondin and TGF-β increase expression of urokinase type plasminogen activator (uPA) and its inhibitor (PAI-1) in human breast cancer. American Association for Cancer Research - 85th Annual Meeting, San Francisco, California, 1994 April.
4. Computer-assisted image analysis of tumor sections for a new

thrombospondin receptor. Society of Head and Neck Surgeons and European Organization for Research and Treatment of Cancer Joint Meeting - Paris, France, 1994 May.

6. Thrombospondin-1 in squamous cell carcinomas of the head and neck: effects on production of plasminogen activator inhibitor type-1 and tumor cell adhesion. Society of University Surgeons – 40th Annual Residents Conference, Milwaukee, Wisconsin, 1998 February.

7. Thrombospondin-1 in squamous cell carcinomas of the head and neck: effects on production of plasminogen activator inhibitor type-1 and tumor cell adhesion. American College of Surgeons – Surgical Forum – 84th Annual Clinical Congress, Orlando, Florida, 1998 October.

# Transcriptional regulation of urokinase plasminogen activator (uPA) by TGF-β and thrombospondin-1 (TSP-1) in breast cancer. Proceedings of the Cancer Forum, Society of Surgical Oncology 52nd Annual Meeting, Orlando, Florida, 1999 March.

1. Stromal cyclooxygenase-2 (COX-2): a target for colon cancer chemoprevention? Proceedings of the Cancer Forum, Society of Surgical Oncology 54th Annual Meeting, Washington, D.C., 2001 March.
2. Preoperative chemo-radiation in the management of adenocarcinoma of the body of the pancreas. Midwest Surgical Association 44th Annual Meeting, Lake Geneva, Wisconsin, 2001 August.
3. Hypermethylation of the MED1 DNA repair gene promoter in ovarian cancer. Proceedings of the Cancer Forum, Society of Surgical Oncology 55 th Annual Meeting, Denver, Colorado, 2002 March.
4. *Sprouty4A*, a novel genetic marker of response to imatinib mesylate in gastrointestinal stromal tumors. Proceedings of the Cancer Forum, Society of Surgical Oncology 56th Annual Meeting, Los Angeles, California, 2003 March.
5. COX-2 expression and clinical outcome in mesenchymal tumors of the gastrointestinal tract. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, San Francisco, California, 2004 January.
6. Mechanisms of resistance to Erbitux (Anti-EGFR) combination therapy in pancreatic adenocarcinoma cells. Proceedings of the Society for Surgery of the Alimentary Tract, New Orleans, Louisiana, 2004 May.
7. Hypermethylation of *MED-1* tumor suppressor genes is associated with colorectal cancer progression. American Association for Cancer Research 97th Annual Meeting, Washington D.C., 2006 April.
8. Improved response of pancreatic adenocarcinoma cells to combined ErbB receptor molecular targeting. American Association for Cancer Research 97th Annual Meeting, Washington D.C., 2006 April.
9. Absence of *EGFR* activating mutations and aberrant EGFR pathway signaling in pancreatic cancer specimens. American Association for Cancer Research 97th Annual Meeting, Washington D.C., 2006 April.
10. Mechanisms of aberrant epidermal growth factor receptor (EGFR) signaling in the absence of *EGFR* activating mutations in pancreatic cancer patients. Surgical Forum, American College of Surgeons Clinical Congress, Chicago, Illinois, 2006 October.
11. *EGFR* genomic gain and aberrant pathway signaling in pancreatic cancer patients. 2nd Academic Surgical Congress, Phoenix, Arizona, 2007 February.
12. Pancreatic cancer epidermal growth factor receptor (*EGFR*) intron 1 polymorphism influences clinical outcome and response to erlotinib. Proceedings of the Cancer Forum, Society of Surgical Oncology 60th Annual Meeting, Washington, DC, 2007 March. Recipient of Best Paper Award and Harvey Baker Travel Award for residents (Ching-Wei Tzeng, MD)
13. ErbB signaling in pancreatic cancer patients: implications for EGFR-targeted therapy. The Pancreas Club, Washington, DC, 2007 May.
14. Neuregulin-associated pancreatic cancer ErbB3 pathway activation influences erlotinib sensitivity *in vitro* and postoperative patient survival. Proceedings of the Society for Surgery of the Alimentary Tract, Washington, DC, 2007 May.

23. ErbB3 promotes tumorigenesis in pancreatic adenocarcinoma. Proceedings of the 3rd Academic Surgical Congress, Fort Myers, Florida, 2009 February.

24. Stromal neuregulin-1 (NRG-1) induces ErbB3-mediated resistance to erlotinib therapy in pancreatic cancer. Proceedings of the Cancer Forum, Society of Surgical Oncology 62nd Annual Meeting, Phoenix, Arizona, 2009 March.

25. Stromal activated fibroblasts promote pancreatic cancer proliferation and erlotinib resistance through ErbB3 signaling. Surgical Forum, American College of Surgeons 95th Annual Clinical Congress, Chicago, Illinois, 2009 October.

26. Markers of KIT inhibition in gastrointestinal stromal tumors (GIST). Surgical Forum, American College of Surgeons Clinical Congress, Chicago, Illinois, 2009 October.

27. MM-121, a monoclonal anti-ErbB3 antibody, inhibits tumor progression in a murine model of human pancreatic adenocarcinoma. Proceedings of the Cancer Forum, Society of Surgical Oncology 64th Annual Meeting, San Antonio, Texas, 2011 March.

28. Targeting ErbB receptor-mediated stromal-tumor interaction in pancreatic ductal adenocarcinoma (PDAC). The Pancreas Club, Chicago, Illinois, May 2011.

29. Dual EGFR/ErbB3 targeting effectively inhibits tumor progression in pancreatic ductal adenocarcinoma (PDAC). Surgical Forum, American College of Surgeons 97th Annual Clinical Congress, San Francisco, California, 2011 October.

30. Endoscopic ultrasound (EUS) evaluation in the surgical treatment of duodenal and peri-ampullary adenomas.The Pancreas Club, San Diego, California, May 2012.

31. Multi-targeted approaches in the treatment of pancreatic ductal adenocarcinoma. The Pancreas Club, Orlando, Florida, May 2013.

32. Outcomes of Laparoscopic Colectomy in the Elderly: Analysis of the National Inpatient Sample.  SAGES, Baltimore, Maryland, 2013.

33. Single-port gastrostomy tube placement with the TransEnterix SPIDER device. SAGES, Baltimore, Maryland, 2013.

34. National Trends of Pancreatic Cystic Lesions Over an 18-Year Period. Americas Hepato-Pancreato-Biliary Association, Miami, Florida, 2013.

35. Financial Implications of Common Bile Duct Injuries during Cholecystectomy: Analysis of the Nationwide Inpatient Sample Over a 10-Year Period. Americas Hepato-Pancreato-Biliary Association, Miami, Florida, 2013.

36. Multidisciplinary Management of Mediastinal Pancreatic Pseudocysts: A case Report and Review of the literature. Americas Hepato-Pancreato-Biliary Association, Miami, Florida, 2013.

37. Difference in Hospital Charges and Length of stays in Patients Undergoing Open Versus Laparoscopic Radiofrequency Ablation. Americas Hepato-Pancreato-Biliary Association, Miami, Florida, 2013.

38. Disposition Following Esophageal Resection for Cancer. 66th Annual cancer Sympsium. Society of Surgical Oncology, National Harbor, Maryland, 2013.

39. Ascites Is A Risk Factor for Increased Postoperative Morbidity and Mortality in Patients That Undergo Pancreatic Necrosectomy for Acute Pancreatic Necrosis, Association for Academic Surgery, San Francisco, California, 2014.

40. Hospital readmissions rates following open and laparoscopic cholecystectomy. Americas Hepato-Pancreato-Biliary Association, Miami, Florida, 2014.

41. Tumor stage at presentation and access to surgery is not influenced by race in pancreatic cancer patients. Americas Hepato-Pancreato-Biliary Association, Miami, Florida, 2014.

42. Regionalization of HPB cancer treatment within the State of Florida according to the American College of Surgeons Commission on Cancer Accreditation. Americas Hepato-Pancreato-Biliary Association, Miami, Florida, 2014.

43. General Surgery Resident Participation in complex pancreatic cases. Americas Hepato-

Pancreato-Biliary Association, Miami, Florida, 2014.

44. The use and utility of abdominal CT scans in the immediate postoperative period following

pancreatic resections. Americas Hepato-Pancreato-Biliary Association, Miami, Florida, 2014.

45. Pancreatic cancer cells scavenge lysophospholipids from stroma in the hypoxic tumor microenvironment. AACR Special Conference on Pancreatic Cancer, Orlando, Florida 2016.

46. Active Chromatin *K-RAS* Mutant Gene detected in Pancreatic Juice from Patients with Peri-Ampullary Neoplasms. 13th Annual Academic Surgical Congress, Jacksonville, Florida, 2018.

47. Cholecystectomy after Walled-Off Pancreatic Necrosis. Americas Hepato-

Pancreato-Biliary Association, Miami, Florida, 2018.

48. Portal Vein Circulating Tumor Cells (CTC) Conform Multi-Cellular Type Clusters in Patients with Peri-Ampullary Carcinomas. Society of Surgical Oncology Annual Meeting, Chicago, Illinois, 2018.

49. Exploring the Microenvironment of the Portal Venous Circulation in Pancreatic Cancer: Circulating tumor cell/Immune cell Interactions. Pancreas Club, Washington DC, 2018.

50. Circulating tumor cell-myeloid fibroblast interactions in portal blood of pancreatic cancer patients. Edward Copeland, MD, Best Basic Science Abstract. Florida Chapter, American College of Surgeons, Orlando, FL, 2020.